BioSpace News Archive

Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.

Lyra Therapeutics, Inc. today announced completion of enrollment in the Phase 2 BEACON clinical trial of LYR-220 in adult patients with CRS who have had prior sinus surgery.

scPharmaceuticals Inc. announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.

Revolo Biotherapeutics today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy of Allergy Asthma and Immunology (AAAAI) Annual Meeting, which is being held February 24-27 in San Antonio, Texas.

PDS Biotechnology Corporation announced that an abstract investigating the ability of PDS0101 in combination with KEYTRUDA® to induce HPV16-specific CD4 and CD8 T cell activation and functionality has been accepted for presentation at the ESMO Targeted Anticancer Therapies Congress 2023 in Paris, March 6-8, 2023.

Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that the Company will present additional data from the open-label extension (OLE) of AP-0101, a Phase 2a study of SerpinPC, a novel inhibitor of activated protein C (APC) being developed for the treatment of hemophilia, during an oral presentation at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), on February 10, 2023.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023.

NewAmsterdam Pharma Company N.V. announced the appointment of John W. Smither as an independent director to its Board of Directors.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities Global Biopharma Conference.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several international events on February-March.